Cargando…

SILAC-Based Proteomic Profiling of the Human MDA-MB-231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms: The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin

BACKGROUND: Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. While lactoferrin has been shown to exert its function by activating differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoedt, Esthelle, Chaoui, Karima, Huvent, Isabelle, Mariller, Christophe, Monsarrat, Bernard, Burlet-Schiltz, Odile, Pierce, Annick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130549/
https://www.ncbi.nlm.nih.gov/pubmed/25116916
http://dx.doi.org/10.1371/journal.pone.0104563
_version_ 1782330343231062016
author Hoedt, Esthelle
Chaoui, Karima
Huvent, Isabelle
Mariller, Christophe
Monsarrat, Bernard
Burlet-Schiltz, Odile
Pierce, Annick
author_facet Hoedt, Esthelle
Chaoui, Karima
Huvent, Isabelle
Mariller, Christophe
Monsarrat, Bernard
Burlet-Schiltz, Odile
Pierce, Annick
author_sort Hoedt, Esthelle
collection PubMed
description BACKGROUND: Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. While lactoferrin has been shown to exert its function by activating different transduction pathways, delta-lactoferrin has been proven to act as a transcription factor. Like many tumor suppressors, these two proteins are under-expressed in several types of cancer, particularly in breast cancer. METHODOLOGY/PRINCIPAL FINDINGS: In order to compare the differential effects of the re-introduction of lactoferrin isoforms in breast cancer cells we chose the cancerous mammary gland MDA-MB-231 cell line as a model. We produced a cell line stably expressing delta-lactoferrin. We also treated these cells with fresh purified human breast lactoferrin. We performed two quantitative proteomic studies in parallel using SILAC coupled to mass spectrometry in order to compare the effects of different doses of the two lactoferrin isoforms. The proteome of untreated, delta-lactoferrin expressing and human lactoferrin treated MDA-MB-231 cells were compared. Overall, around 5300 proteins were identified and quantified using the in-house developed MFPaQ software. Among these, expression was increased by 1.5-fold or more for around 300 proteins in delta-lactoferrin expressing cells and 190 proteins in lactoferrin treated cells. At the same time, about 200 and 40 proteins were found to be downregulated (0-0.7-fold) in response to delta-lactoferrin and lactoferrin, respectively. CONCLUSIONS/SIGNIFICANCE: Re-introduction of delta-lactoferrin and lactoferrin expression in MDA-MB-231 mainly leads to modifications of protein profiles involved in processes such as proliferation, apoptosis, oxidative stress, the ubiquitin pathway, translation and mRNA quality control. Moreover, this study identified new target genes of delta-lactoferrin transcriptional activity such as SelH, GTF2F2 and UBE2E1.
format Online
Article
Text
id pubmed-4130549
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41305492014-08-14 SILAC-Based Proteomic Profiling of the Human MDA-MB-231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms: The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin Hoedt, Esthelle Chaoui, Karima Huvent, Isabelle Mariller, Christophe Monsarrat, Bernard Burlet-Schiltz, Odile Pierce, Annick PLoS One Research Article BACKGROUND: Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. While lactoferrin has been shown to exert its function by activating different transduction pathways, delta-lactoferrin has been proven to act as a transcription factor. Like many tumor suppressors, these two proteins are under-expressed in several types of cancer, particularly in breast cancer. METHODOLOGY/PRINCIPAL FINDINGS: In order to compare the differential effects of the re-introduction of lactoferrin isoforms in breast cancer cells we chose the cancerous mammary gland MDA-MB-231 cell line as a model. We produced a cell line stably expressing delta-lactoferrin. We also treated these cells with fresh purified human breast lactoferrin. We performed two quantitative proteomic studies in parallel using SILAC coupled to mass spectrometry in order to compare the effects of different doses of the two lactoferrin isoforms. The proteome of untreated, delta-lactoferrin expressing and human lactoferrin treated MDA-MB-231 cells were compared. Overall, around 5300 proteins were identified and quantified using the in-house developed MFPaQ software. Among these, expression was increased by 1.5-fold or more for around 300 proteins in delta-lactoferrin expressing cells and 190 proteins in lactoferrin treated cells. At the same time, about 200 and 40 proteins were found to be downregulated (0-0.7-fold) in response to delta-lactoferrin and lactoferrin, respectively. CONCLUSIONS/SIGNIFICANCE: Re-introduction of delta-lactoferrin and lactoferrin expression in MDA-MB-231 mainly leads to modifications of protein profiles involved in processes such as proliferation, apoptosis, oxidative stress, the ubiquitin pathway, translation and mRNA quality control. Moreover, this study identified new target genes of delta-lactoferrin transcriptional activity such as SelH, GTF2F2 and UBE2E1. Public Library of Science 2014-08-12 /pmc/articles/PMC4130549/ /pubmed/25116916 http://dx.doi.org/10.1371/journal.pone.0104563 Text en © 2014 Hoedt et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Hoedt, Esthelle
Chaoui, Karima
Huvent, Isabelle
Mariller, Christophe
Monsarrat, Bernard
Burlet-Schiltz, Odile
Pierce, Annick
SILAC-Based Proteomic Profiling of the Human MDA-MB-231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms: The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin
title SILAC-Based Proteomic Profiling of the Human MDA-MB-231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms: The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin
title_full SILAC-Based Proteomic Profiling of the Human MDA-MB-231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms: The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin
title_fullStr SILAC-Based Proteomic Profiling of the Human MDA-MB-231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms: The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin
title_full_unstemmed SILAC-Based Proteomic Profiling of the Human MDA-MB-231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms: The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin
title_short SILAC-Based Proteomic Profiling of the Human MDA-MB-231 Metastatic Breast Cancer Cell Line in Response to the Two Antitumoral Lactoferrin Isoforms: The Secreted Lactoferrin and the Intracellular Delta-Lactoferrin
title_sort silac-based proteomic profiling of the human mda-mb-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130549/
https://www.ncbi.nlm.nih.gov/pubmed/25116916
http://dx.doi.org/10.1371/journal.pone.0104563
work_keys_str_mv AT hoedtesthelle silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin
AT chaouikarima silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin
AT huventisabelle silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin
AT marillerchristophe silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin
AT monsarratbernard silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin
AT burletschiltzodile silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin
AT pierceannick silacbasedproteomicprofilingofthehumanmdamb231metastaticbreastcancercelllineinresponsetothetwoantitumorallactoferrinisoformsthesecretedlactoferrinandtheintracellulardeltalactoferrin